Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 mRNA-LNP vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: CanSino Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 21, 2020

            Details:

            Under this collaboration, PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niclosamide

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            Purdue University scientist Yuan Yao’s laboratory has developed a solution, a plant-based, highly potent nanoparticle called OHPP (octenylsuccinate hydroxypropyl phytoglycogen) that can solubilize and enable niclosamide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plant based vaccine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: ZYUS Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2020

            Details:

            ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 antibodies

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Government of Canada

            Deal Size: $175.6 million Upfront Cash: Undisclosed

            Deal Type: Funding May 03, 2020

            Details:

            Fund will expand AbCellera's efforts, as more than 500 specific human anti-SARS-CoV-2 antibodies have been established as part of a partnership with the Vaccine Research Center.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifenprodil Tartrate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            The study will be an adaptive pilot to pivotal trial design based on WHO guidance documents to assess whether Ifenprodil will improve clinical symptoms and minimize mortality in COVID-19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ribavirin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            The company believes that since ribavirin is a synthetic nucleoside, It may work to stop viral replication and VIRAZOLE may be effective in reducing the severity of COVID-19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fenretinide

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            Laurent Pharmaceuticals is planning to test its lead drug LAU-7b in patients with COVID-19 disease, as part of a Phase 2 clinical trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bucillamine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 03, 2020

            Details:

            Revive has filed its Pre-Investigational New Drug meeting request with the U.S. Food and Drug Administration for Bucillamine in the treatment of the coronavirus disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SACT-COV19

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aptorum

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 30, 2020

            Details:

            Aptorum with Covar Pharmaceuticals and in alliance with the University of Hong Kong plans to perform more preclinical experiments on selected small drug molecules to combat COVID-19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            The study demonstrates apabetalone to inhibit specialized proteins called bromodomain and extraterminal domain proteins from interacting with a SARS-CoV-2 viral protein.

            PharmaCompass